Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3242 Target Snapshot

Carbonic anhydrase 12 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
5,339Compounds
481Assays
34Approved Drugs
6,066.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Carbonic anhydrase 12 shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O43570. Start with glaucoma, then reuse UniProt O43570 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with glaucoma, then reuse UniProt O43570 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
glaucoma

Carbonic anhydrase 12 shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with glaucoma because it currently carries approved-linked support. Linked drugs include ACETAZOLAMIDE, ACETAZOLAMIDE SODIUM, DICHLORPHENAMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Carbonic anhydrase 12 as ChEMBL target CHEMBL3242, mapped to UniProt O43570. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Carbonic anhydrase 12
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3242
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O43570
Carbonic anhydrase 12
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Carbonic anhydrase 12 is the right protein anchor across sources, using UniProt O43570 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why glaucoma is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCarbonic anhydrase 12
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO43570
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCarbonic anhydrase 12
UniProt AccessionO43570
Component TypeProtein
Sequence Length354 aa

Carbonic anhydrase 12

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Carbonic anhydrase 12, mapped to UniProt O43570. Sequence length is 354 aa.

Mapped IDO43570
Review nameCarbonic anhydrase 12
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Carbonic anhydrase 12 shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
glaucoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugACETAZOLAMIDE
Linked drugACETAZOLAMIDE SODIUM
Linked drugDICHLORPHENAMIDE
Approved-linked Approved
angle-closure glaucoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugACETAZOLAMIDE
Linked drugACETAZOLAMIDE SODIUM
Approved-linked Approved
edema
2 linked drugs · 2 direct · 2 efficacy
Linked drugACETAZOLAMIDE
Linked drugACETAZOLAMIDE SODIUM
Approved-linked Approved
Seizure
2 linked drugs · 2 direct · 2 efficacy
Linked drugACETAZOLAMIDE
Linked drugACETAZOLAMIDE SODIUM
Approved-linked Approved
altitude sickness
1 linked drug · 1 direct · 1 efficacy
Linked drugACETAZOLAMIDE
Approved-linked Approved
congestive heart failure
1 linked drug · 1 direct · 1 efficacy
Linked drugACETAZOLAMIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with glaucoma because it currently carries approved-linked support. Linked drugs include ACETAZOLAMIDE, ACETAZOLAMIDE SODIUM, DICHLORPHENAMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseglaucoma
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

34
Approved
11
Phase III
16
Phase II
5
Phase I
2
Phase 0.5
Assay Mix

Activity Type Distribution

IC50144.0
KI5,356.0
KD566.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4436290 11.0 Kd 0.01 Preclinical
CHEMBL4470832 11.0 Kd 0.01 Preclinical
CHEMBL4586089 11.0 Kd 0.01 Preclinical
CHEMBL4165543 10.89 Kd 0.013 Preclinical
CHEMBL4162451 10.85 Kd 0.014 Preclinical
CHEMBL4176828 10.72 Kd 0.019 Preclinical
CHEMBL4445515 10.72 Kd 0.019 Preclinical
CHEMBL4553519 10.7 Kd 0.02 Preclinical
CHEMBL4565224 10.7 Kd 0.02 Preclinical
CHEMBL4572161 10.7 Kd 0.02 Preclinical
Distribution

pChEMBL Value Distribution

299
5.0
161
5.5
605
6.0
394
6.5
1292
7.0
655
7.5
1612
8.0
211
8.5
225
9.0
27
9.5
pChEMBL
Approved Drugs

Approved Drugs

PAZOPANIB
CHEMBL477772
Approved 2009
Properties Compare Identifier
NILOTINIB
CHEMBL255863
Approved 2007
Properties Compare Identifier
IMATINIB
CHEMBL941
Approved 2001
Properties Compare Identifier
VALDECOXIB
CHEMBL865
Approved 2001
Properties Compare Identifier
ZOLEDRONIC ACID
CHEMBL4303669
Approved 2001
Properties Compare Identifier
ZONISAMIDE
CHEMBL750
Approved 2000
Properties Compare Identifier
BRINZOLAMIDE
CHEMBL220491
Approved 1998
Properties Compare Identifier
CELECOXIB
CHEMBL118
Approved 1998
Properties Compare Identifier
DORZOLAMIDE
CHEMBL218490
Approved 1994
Properties Compare Identifier
FAMOTIDINE
CHEMBL902
Approved 1986
Properties Compare Identifier
SULFANILAMIDE
CHEMBL21
Approved 1985
Properties Compare Identifier
INDAPAMIDE
CHEMBL406
Approved 1983
Properties Compare Identifier
ETHOXZOLAMIDE
CHEMBL18
Approved 1982
Properties Compare Identifier
MAFENIDE
CHEMBL419
Approved 1969
Properties Compare Identifier
FUROSEMIDE
CHEMBL35
Approved 1966
Properties Compare Identifier
CHLORTHALIDONE
CHEMBL1055
Approved 1960
Properties Compare Identifier
TRICHLORMETHIAZIDE
CHEMBL1054
Approved 1960
Properties Compare Identifier
METHAZOLAMIDE
CHEMBL19
Approved 1959
Properties Compare Identifier
DICHLORPHENAMIDE
CHEMBL17
Approved 1958
Properties Compare Identifier
ACETAZOLAMIDE
CHEMBL20
Approved 1953
Properties Compare Identifier
Assay Landscape

Assay Landscape

481
Total Assays
4,728
Tested Compounds
2
Assay Types
Binding — 477 assays, 4,728 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 414 4,359 7.3
assay format 58 337 7.8
cell-based format 5 32 6.8
ADME — 4 assays, 53 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 20 6.8
single protein format 2 33 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine